Quantcast
Last updated on April 24, 2014 at 16:01 EDT

Latest Takeda Pharmaceuticals Stories

2014-04-20 23:01:49

Huge amount of damages awarded to New York man who was diagnosed with bladder cancer that jurors were told was caused by diabetes drug Actos. National network of attorneys continues offer of no-cost consultations to consumers seeking compensation over similar claims. San Diego, CA (PRWEB) April 20, 2014 http://www.resource4thepeople.com/defectivedrugs/Actos-Bladder-Cancer-Lawsuit.html Resource4thePeople today announced that it is providing consumers who may have been affected by Actos...

2014-04-16 23:10:18

The Japanese drug maker that was recently ordered to pay $6 billion to a man who claimed that his bladder cancer diagnosis was caused by Actos, makes several other drugs with the same active ingredient. (PRWEB) April 16, 2014 The diabetes drug Actos has made news headlines this week after a jury decided that its manufacturer, Takeda, was responsible for causing bladder cancer in this case. But Actos is just one of several pioglitazone-containing drugs produced by Takeda and all of them...

2014-04-08 23:01:24

Takeda Pharmaceuticals and marketing partner Eli Lilly & Co. were ordered to pay a total of $9 billion in punitive damages for allegedly withholding information about the potential risks associated with the diabetes drug Actos. Flood Law Group says it agrees with the decision and is available to investigate potential Actos bladder cancer lawsuits. Washington, D.C. (PRWEB) April 08, 2014 A U.S. jury ordered Takeda Pharmaceuticals and marketing partner Eli Lilly & Co. to pay a total...

2014-03-28 23:25:00

Nevada case involves allegations that women developed cancer as a result of Actos medication. National network of attorneys is offering no-cost consultations to consumers seeking compensation over similar claims. San Diego, CA (PRWEB) March 28, 2014 http://www.resource4thepeople.com/defectivedrugs/Actos-Bladder-Cancer-Lawsuit.html Resource4thePeople today announced its latest update for consumers following litigation involving allegations that the use of Actos to treat diabetes can cause...

2014-02-08 23:03:08

National network of attorneys is providing consumer updates and no-cost consultations over allegations that the use of the diabetes medication Actos can cause patients to develop bladder cancer. San Diego, CA (PRWEB) February 08, 2014 http://www.resource4thepeople.com/defectivedrugs/Actos-Bladder-Cancer-Lawsuit.html Resource4thePeople today announced today its latest update for consumers who are following litigation* involving allegations that the use of Actos to treat diabetes can cause...

2014-02-02 23:00:56

The Firm is filing Actos lawsuits on behalf of individuals who took Actos for an extended period of time, and allegedly developed bladder cancer due to their use of the Type 2 diabetes medication. New York, New York (PRWEB) February 02, 2014 The federal judge overseeing thousands of Actos lawsuits has ruled that jurors hearing the first federal bellwether trial (http://www.consumerinjurylawyers.com/actos/Actos-Lawsuit.html) will be told that Takeda Pharmaceuticals intentionally destroyed...

2014-01-09 23:25:29

National network of attorneys will resume availability in connection with consumer inquiries over allegations that the use of the diabetes medication Actos can cause patients to develop bladder cancer. San Diego, CA (PRWEB) January 09, 2014 http://www.resource4thepeople.com/defectivedrugs/Actos-Bladder-Cancer-Lawsuit.html Resource4thePeople today announced today that its national network of attorneys will continue to offer no-cost consultations in 2014 to consumers who are seeking...

2014-01-08 08:25:23

Hart's significant pharmaceutical sales and marketing experience to strengthen Delta Point's focus as top tier consulting firm MALVERN, Pa., Jan. 8, 2014 /PRNewswire/ -- Dean Hart, former Senior Vice President Sales at Takeda Pharmaceuticals North America (TPNA), has joined Delta Point as Senior Vice President. "Dean has had quite an impressive career in pharmaceuticals and in the life science industry start-up organizations," explains Jerry Acuff, founder and CEO of Delta Point....

2014-01-07 08:30:44

SAN DIEGO, Jan. 7, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), today announced that the United States Food and Drug Administration (FDA) considers the recent resubmission of the Contrave® (naltrexone sustained release (SR)/bupropion SR) New Drug Application to be a complete response to the FDA's prior January 31, 2011 action letter. For the resubmission, the FDA has assigned a Prescription Drug User Fee Act goal date of June 10, 2014. If approved, the Company...

2013-12-11 08:30:22

SAN DIEGO, Dec. 11, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the Company has resubmitted the Contrave® New Drug Application to the United States (U.S.) Food and Drug Administration (FDA). Investigational drug Contrave (naltrexone sustained release (SR) / bupropion SR) is being developed for weight loss and maintenance of weight loss. The resubmission follows the November 25, 2013 announcement of the successful interim analysis of the...